文献速递泌尿男性生殖肿瘤

小肾癌的当前管理:患者选择、肾肿瘤活检、主动监测与热消融

Current Management of Small Renal Masses, Including Patient Selection, Renal Tumor Biopsy, Active Surveillance, and Thermal Ablation.
PubMed 文献 · J Clin Oncol · 2018-10-29

肾癌占所有癌症的2%至3%,发病率上升,影像学普及导致偶发小肾癌(SRMs)临床困境。SRMs为异质性肿瘤,涵盖良性、惰性及侵袭性,目前无复合模型或生物标志物在治疗选择前准确预测肾癌诊断,肾肿瘤活检存争议。本文综述共识指南与近期文献,聚焦患者治疗选择、活检、主动监测与热消融,并强调识别高死亡风险患者及减少过度治疗的机会。

要点

  • 小肾癌异质性大,涵盖良性至侵袭性肿瘤,治疗前缺乏准确预测模型或生物标志物。
  • 肾肿瘤活检应用仍存争议,需结合患者选择与主动监测、热消融等策略综合决策。
  • 近二十年对小肾癌生物学及竞争死亡风险认识提高,管理方式发生显著变化。

核心结论

  • 小肾癌管理需综合患者选择、肾肿瘤活检、主动监测和热消融,以平衡肿瘤控制与过度治疗风险。

研究设计与样本

  • 综述类研究,批判性评估已发表的共识指南和近期关于小肾癌诊断与管理的文献。

主要发现

  • 肾癌占所有癌症的2%至3%,发病率上升,影像学普及导致偶发小肾癌增多。
  • 小肾癌为异质性肿瘤群,涵盖良性、惰性和更具侵袭性的肿瘤。
  • 目前无复合模型或生物标志物能在治疗选择前准确预测肾癌诊断,肾肿瘤活检使用仍存争议。
  • 近二十年来,随着对肿瘤生物学和竞争死亡风险的理解改善,小肾癌管理发生显著变化。

临床怎么用

  • 临床需综合评估患者选择、肾肿瘤活检、主动监测和热消融,以优化小肾癌管理。
  • 应关注识别小肾癌中高肾癌相关死亡风险的患者,并尽量减少过度治疗和患者发病率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Renal cancer represents 2% to 3% of all cancers, and its incidence is rising. The increased use of ultrasonography and cross-sectional imaging has resulted in the clinical dilemma of incidentally detected small renal masses (SRMs). SRMs represent a heterogeneous group of tumors that span the full spectrum of metastatic potential, including benign, indolent, and more aggressive tumors. Currently, no composite model or biomarker exists that accurately predicts the diagnosis of kidney cancer before treatment selection, and the use of renal mass biopsy remains controversial. The management of SRMs has changed dramatically over the last two decades as our understanding of tumor biology and competing risks of mortality in this population has improved. In this review, we critically assess published consensus guidelines and recent literature on the diagnosis and management of SRMs, with a focus on patient treatment selection and use of renal mass biopsy, active surveillance, and thermal ablation. Finally, we highlight important opportunities for leveraging recent research discoveries to identify patients with SRMs at high risk for renal cell carcinoma-related mortality and minimize overtreatment and patient morbidity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sanchez A, Feldman AS, Hakimi AA, et al. Current Management of Small Renal Masses, Including Patient Selection, Renal Tumor Biopsy, Active Surveillance, and Thermal Ablation. J Clin Oncol. 2018. PMID: 30372390. doi:10.1200/JCO.2018.79.2341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。